WHO’s rollout of malaria vaccine in Africa: can safety questions be answered after only 24 months?
Key messagesPhase III trials of the RTS,S malaria vaccine identified three safety concerns: higher risks of meningitis, cerebral malaria, and doubled female mortalityThese safety concerns are now…
